XTL Biopharmaceuticals Announces Top-Line Results From the Bicifadine Phase 2b Study for Diabetic Neuropathic Pain
November 18 2008 - 7:05AM
PR Newswire (US)
Study failed to meet its primary endpoint VALLEY COTTAGE, N.Y.,
Nov. 18 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd.
(NASDAQ:XTLB)(TASE:XTL) announced today the top-line results from
the Bicifadine Phase 2b clinical trial for the treatment of
diabetic neuropathic pain. The trial's primary objective was to
compare the efficacy of two doses of Bicifadine against placebo in
reducing pain associated with diabetic neuropathy. The primary
endpoint of the study was the reduction in pain score during the
course of treatment. The company announced that the study failed to
meet its primary endpoint. The trial also failed to meet key
secondary analysis. Ron Bentsur, CEO of the company, commented: "We
are all very disappointed with the results of the study. We will
devote the next few days to further analyze the data and decide on
the appropriate course of action for the Bicifadine program, and
for the company." DATASOURCE: XTL Biopharmaceuticals Ltd. CONTACT:
Ron Bentsur, Chief Executive Officer of XTL Biopharmaceuticals
Ltd., +1-845-267-0707 ext. 225
Copyright
XTL Biopharmaceuticals (NASDAQ:XTLB)
Historical Stock Chart
From Jun 2024 to Jul 2024
XTL Biopharmaceuticals (NASDAQ:XTLB)
Historical Stock Chart
From Jul 2023 to Jul 2024